Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | FABP3 | P05413 | 3/20 | 0.53 |
| ▸ | FABP4 | P15090 | 3/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320894 | 0.89 | FABP3 (0.55) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL3316451 | 0.86 | LMNA (0.66) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL3318172 | 0.86 | FABP4 (0.72) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL3321046 | 0.75 | FABP3 (0.56) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL10659554 | 0.74 | LMNA (0.64) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL10659561 | 0.74 | LMNA (0.64) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL10657576 | 0.74 | LMNA (0.64) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL386416 | 0.73 | MAP2 (0.53) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL31442524 | 0.73 | FABP3 (0.62) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A | |
| SCHEMBL10658955 | 0.72 | LMNA (0.60) | SMN1; SMN2LMNAFABP3FABP4PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | claimed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | claimed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | claimed |
| WO-2010056865-A1 | QUINOLINE DERIVATIVES AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-8865739-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8664399-B2 | Substituted heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056865-A1 | QUINOLINE DERIVATIVES AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107155-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | SMN1; SMN2 2201/4885LMNA 880/4885FABP3 1216/4885 |
| US-20100125091-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | SMN1; SMN2 2201/4885LMNA 880/4885FABP3 1216/4885 |
| US-20130102632-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNH2, KCNJ2, CACNA1E | SMN1; SMN2 2201/4885LMNA 880/4885FABP3 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.